Guizhou Bailing Group Pharmaceutical Co.,Ltd. (002424.SZ) has announced that its wholly-owned subsidiary, Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration.

The notice confirms that the clinical trial application for Tangning Tongluo Cream meets the relevant requirements for drug registration. Upon further refinement of the clinical trial protocol, approval has been granted to conduct trials for the treatment of diabetic foot ulcers.

This approval marks a significant milestone in the research and development pipeline for the Tangning Tongluo series, representing a key phased achievement. It facilitates the advancement of the company's "oral plus topical" treatment system for diabetic complications. The receipt of clinical trial approval for the cream is not expected to have a material impact on the company's current-period financial results.